Medidata has announced the renewal of its collaboration with Thermo Fisher Scientific’s PPD clinical research business to expedite innovation in clinical trials.
This collaboration is set to enhance drug development programmes by leveraging the comprehensive Medidata Platform, along with Medidata Adjudicate and additional Medidata Rave offerings.
Medidata Platform is designed to connect sites, patients, sponsors, and partners within a safe and scalable Cloud environment. This approach facilitates the delivery of life-changing therapies for the needy.
The platform streamlines study management from start to finish, eliminating the need for spreadsheets, data reconciliation, and multiple logins.
Medidata Adjudicate, fully integrated with the Medidata Platform, acts as a one-stop clinical endpoint adjudication system.
It supports the entire clinical event lifecycle, from initial collection to outcome, aiding various stakeholders, including investigator sites, sponsors, CROs, data managers, and Clinical Endpoint Committees (CEC).
A pivotal aspect of the renewed collaboration is the advancement of PPD TrueCast, a business solution powered by Medidata AI. TrueCast aims to reduce study timelines by integrating patient recruitment with site performance data, providing predictive models and advanced analytics.
Since 2009, Medidata has collaborated with PPD's clinical research business on more than 1,000 clinical studies across diverse therapeutic areas, including oncology and vaccines.
The extension of this partnership follows a recent collaboration between Medidata and Sanofi Vaccines, which integrated the former’s electronic clinical outcome assessment (eCOA) into Sanofi's vaccine studies.
This move builds upon the existing relationship between Medidata and Sanofi for the use of Medidata Rave electronic data capture (EDC) solutions.
Medidata global sales executive vice-president and head Janet Butler said: “Over the past 15 years, we have built a valued connection with the PPD clinical research business to enhance visibility and decision-making during clinical trials.
“We look forward to working together to complete studies faster, boost drug development productivity, and ultimately bring life-changing treatments to patients sooner.”
